Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model

Chest

Volumn 152, Issue 5, 2017, Pages 999-1007

  Morisset, Julie ^a   Vittinghoff, Eric ^a   Elicker, Brett M ^a   Hu, Xiaowen ^b   Le, Stephanie ^a   Ryu, Jay H ^b   Jones, Kirk D ^a   Haemel, Anna ^a   Golden, Jeffrey A ^a   Boin, Francesco ^a   Ley, Brett ^a   Wolters, Paul J ^a   King, Talmadge E ^a   Collard, Harold R ^a   Lee, Joyce S ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

interstitial lung disease; prognosis; risk prediction; systemic sclerosis

Indexed keywords

CARBON MONOXIDE;

ADULT; AGE; ANAMNESIS; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LONGITUDINAL STUDY; LUNG DIFFUSION CAPACITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RISK; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCLERODERMA; SCORING SYSTEM; SMOKING; TIME OF DEATH; CAUSE OF DEATH; CLINICAL TRIAL; COMPLICATION; DISEASE EXACERBATION; EPIDEMIOLOGY; FOLLOW UP; MORTALITY; MULTICENTER STUDY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SYSTEMIC SCLEROSIS; TIME FACTOR; TRENDS; UNITED STATES; X-RAY COMPUTED TOMOGRAPHY;

CAUSE OF DEATH; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SCLERODERMA, SYSTEMIC; SURVIVAL RATE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES;

EID: 85033576497     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2017.06.009     Document Type: Article

References (40)

1. Steen, V.D., Medsger, T.A., Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66:7 (2007), 940–944.
2. Solomon, J.J., Olson, A.L., Fischer, A., Bull, T., Brown, K.K., Raghu, G., Scleroderma lung disease. Eur Respir Rev 22:127 (2013), 6–19.
3. White, B., Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 29:2 (2003), 371–390.
4. Khanna, D., Tseng, C.H., Farmani, N., et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum 63:10 (2011), 3078–3085.
5. Steen, V.D., Conte, C., Owens, G.R., Medsger, T.A. Jr., Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37:9 (1994), 1283–1289.
6. Plastiras, S.C., Karadimitrakis, S.P., Ziakas, P.D., Vlachoyiannopoulos, P.G., Moutsopoulos, H.M., Tzelepis, G.E., Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 55:4 (2006), 598–602.
7. Man, A., Davidyock, T., Ferguson, L.T., Ieong, M., Zhang, Y., Simms, R.W., Changes in forced vital capacity over time in systemic sclerosis: application of group-based trajectory modelling. Rheumatology 54:8 (2015), 1464–1471.
8. Al-Dhaher, F.F., Pope, J.E., Ouimet, J.M., Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 39:4 (2010), 269–277.
9. Bouros, D., Wells, A.U., Nicholson, A.G., et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165:12 (2002), 1581–1586.
10. Fischer, A., Swigris, J.J., Groshong, S.D., et al. Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest 134:3 (2008), 601–605.
11. Goh, N.S., Desai, S.R., Veeraraghavan, S., et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177:11 (2008), 1248–1254.
12. Launay, D., Humbert, M., Berezne, A., et al. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. Chest 140:4 (2011), 1016–1024.
13. Goh, N.S., Veeraraghavan, S., Desai, S.R., et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 56:6 (2007), 2005–2012.
14. 2) and predicts mortality in systemic sclerosis. Thorax 64:7 (2009), 626–630.
15. Trad, S., Amoura, Z., Beigelman, C., et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 54:1 (2006), 184–191.
16. Fertig, N., Domsic, R.T., Rodriguez-Reyna, T., et al. Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum 61:7 (2009), 958–965.
17. Winstone, T.A., Assayag, D., Wilcox, P.G., et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 146:2 (2014), 422–436.
18. Ley, B., Ryerson, C.J., Vittinghoff, E., et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Internal Med 156:10 (2012), 684–691.
19. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:5 (1980), 581–590.
20. van den Hoogen, F., Khanna, D., Fransen, J., et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65:11 (2013), 2737–2747.
21. Galiè, N., Hoeper, M.M., Humbert, M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30:20 (2009), 2493–2537.
22. Raghu, G., Collard, H.R., Egan, J.J., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:6 (2011), 788–824.
23. Desai, S.R., Veeraraghavan, S., Hansell, D.M., et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 232:2 (2004), 560–567.
24. Harrell, F.E. Jr., Lee, K.L., Mark, D.B., Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:4 (1996), 361–387.
25. Tashkin, D.P., Volkmann, E.R., Tseng, C.H., et al. Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. Ann Rheum Dis 75:2 (2016), 374–381.
26. Tashkin, D.P., Elashoff, R., Clements, P.J., et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:25 (2006), 2655–2666.
27. Thakkar, V., Stevens, W., Prior, D., et al. The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. Arthritis Res Ther, 15(6), 2013, R193.
28. Mukerjee, D., St George, D., Knight, C., et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology 43:4 (2004), 461–466.
29. Hudson, M., Lo, E., Lu, Y., Hercz, D., Baron, M., Steele, R., Cigarette smoking in patients with systemic sclerosis. Arthritis Rheum 63:1 (2011), 230–238.
30. Chaudhary, P., Chen, X., Assassi, S., et al. Cigarette smoking is not a risk factor for systemic sclerosis. Arthritis Rheum 63:10 (2011), 3098–3102.
31. Antoniou, K.M., Hansell, D.M., Rubens, M.B., et al. Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am J Respir Crit Care Med 177:2 (2008), 190–194.
32. Cottin, V., Nunes, H., Mouthon, L., et al. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum 63:1 (2011), 295–304.
33. Moore, O.A., Goh, N., Corte, T., et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology 52:1 (2013), 155–160.
34. Ryerson, C.J., O'Connor, D., Dunne, J.V., et al. Predicting mortality in systemic sclerosis-associated interstitial lung disease using risk prediction models derived from idiopathic pulmonary fibrosis. Chest 148:5 (2015), 1268–1275.
35. du Bois, R.M., Albera, C., Bradford, W.Z., et al. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J 43:5 (2014), 1421–1429.
36. Kim, E.S., Choi, S.M., Lee, J., et al. Validation of the GAP score in Korean patients with idiopathic pulmonary fibrosis. Chest 147:2 (2015), 430–437.
37. Kishaba, T., Shimaoka, Y., Fukuyama, H., et al. Clinical characteristics of idiopathic pulmonary fibrosis patients with gender, age, and physiology staging at Okinawa Chubu Hospital. J Thorac Dis 7:5 (2015), 843–849.
38. Salazar, G.A., Assassi, S., Wigley, F., et al. Antinuclear antibody-negative systemic sclerosis. Semin Arthritis Rheum 44:6 (2015), 680–686.
39. Ho, K.T., Reveille, J.D., The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 5:2 (2003), 80–93.
40. Hamaguchi, Y., Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol 37:1 (2010), 42–53.